AZ does distribution deals for Oxford Covid vaccine

Latest

AZ does distribution deals for Oxford Covid vaccine

In Latest

AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s Covid-19 vaccine, with deliveries starting by the end of 2020.

Oxford University last month announced the start of a Phase II/III UK trial of the vaccine, AZD1222, in about 10,000 adult volunteers. Other late-stage trials are due to begin in a number of countries. AstraZeneca (AZ) says it “recognises that the vaccine may not work but is committed to progressing the clinical programme with speed and scaling up manufacturing at risk”.

AZD1222 has been developed by Oxford University’s Jenner Institute, working with the Oxford Vaccine Group. It uses a replication-deficient viral vector based on a weakened version of a common cold (adenovirus) virus that causes infections in chimpanzees, and contains the genetic material of SARS-CoV-2 spike protein. After vaccination, the surface spike protein is produced, priming the body's immune system to attack Covid-19 if it later infects the body.

The recombinant adenovirus vector (ChAdOx1) was chosen to generate a strong immune response from a single dose. It is not replicating, so cannot cause an ongoing infection in the vaccinated individual.

Vaccines made from the ChAdOx1 virus have been given to more than 320 people to date and have been shown to be well tolerated, although they can cause temporary side effects such as a temperature, influenza-like symptoms, headache or a sore arm. AZ chief executive Pascal Soriot has said the potential vaccine is likely to provide protection against contracting Covid-19 for about a year.

AZ is building a number of supply chains across the world, including Europe, and is seeking to expand manufacturing capacity further. It says it is open to collaborating with other companies in order to meet its commitment to support access to the vaccine at no profit during the pandemic.

The company has recently completed supply agreements with the UK, US, the Coalition for Epidemic Preparedness Innovations and Gavi, the Vaccine Alliance, for 700 million doses, and it agreed a licence with the Serum Institute of India for the supply of an additional one billion doses, principally for low- and middle-income countries. Total manufacturing capacity currently stands at two billion doses.

Record my learning outcomes

Latest

Inspiring stories related to health, fitness and the pursuit of wellbeing

Share:

More like this

bookmark_icon_off
Latest

Dukes to leave PSNC in September

PSNC chief executive Simon Dukes will leave his post at the end of September after just over three and-a-half years in the role.

1 Min Article

bookmark_icon_off
Latest

PDA reports 50 pharmacy closures in one week

Short notice closures appear to be more common in multiples, says PDA.

1 Min Article

bookmark_icon_off
Latest

Coronavirus pharmacy tests spark debate

The company says there is strong interest in its £175 kits, but some pharmacists have been critical.

1 Min Article

bookmark_icon_off
Latest

RPS: Government must act on second BAME Covid report

EPB chair Claire Anderson urges the government to “urgently” act on a report on Covid-19`s impact on BAME communities.

1 Min Article

bookmark_icon_off
Latest

Drug alert: Defect in Emerade devices

There is a risk of some Emerade syringes failing to deliver adrenaline doses due to blockage of the needle, the MHRA warns.

1 Min Article

bookmark_icon_off
Latest

PSNC to hold roadshows to explain five-year deal

A series of roadshows will help pharmacists understand how the five-year settlement will impact their pharmacies.

1 Min Article

Recommended Learning

bookmark_icon_off
Bayer Business Programme

Make it Count: Team Member version

Find out new insights into the consumers of today and explore how, by taking a customer-first approach, you can add value and help build a loyal customer base.

15 Min Module

bookmark_icon_off
Sponsored education

Skincare training for pharmacy

Delve into dry skin management and understand how you can make a difference to customers looking for advice, support and product recommendations to help manage their compromised skin.

15 Min Module

bookmark_icon_off
Sponsored education

Abdominal discomfort: Multi-symptom relief with Buscomint

Discover the key benefits of a product that offers multi-symptom relief from abdominal pain, cramps and bloating, plus lifestyle advice to help manage symptoms.

5 Min Module

bookmark_icon_off
Sponsored education

Next-level parasite protection for dogs

Explore the FRONTLINE Tri-Act® active pack to learn about next-level parasite protection for dogs.

10 Min Module

bookmark_icon_off
Videos

Advising on thrush treatment

This video looks at the distinctive benefits of different combination products and how to find the right treatment option for your customer.

7 Min Module

bookmark_icon_off
Sponsored education

How to advise on head lice

Despite them being so common, many people still don't know how to get rid of head lice. This training will arm you with the facts so that you can help customers choose the best treatments and answer their questions with confidence.

15 Min Module